Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (M15-563)
jRCT2080224703Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of tilavonemab in progressive supranuclear palsy (PSP), sponsored by AbbVie Inc. Started May 2019; status: terminated.
02
Drugs
tilavonemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on jRCT2080224703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224703.